Related Experiment Video
Updated: Apr 15, 2026
07:48
Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
Published on: July 3, 2015
9.3K
Redressing the inequities in Canadian pharmacare.
1The Cameron Institute, Cambridge, Ontario, Canada. dwaynetaylor@rogers.com.
Healthcare Management Forum
|April 4, 2015
Summary
Canadian healthcare access to prescription drugs is not universal, creating significant financial burdens for patients needing orphan drugs and oral cancer treatments. This article explores the causes and solutions for pharmaceutical payment disparities.
Area of Science:
- Health Policy
- Pharmaceutical Economics
- Canadian Healthcare System
Background:
- Canadian healthcare is intended to be universal, but drug coverage is a significant gap.
- Lack of universal drug access disproportionately affects patients with rare diseases and those requiring oral cancer medications.
- Patients, survivors, and their families face substantial and increasing financial burdens due to drug costs.
Conclusions:
- The current system fails to ensure universal access to essential pharmaceuticals in Canada.
- Addressing the financial barriers to drug access requires systemic policy changes.
- Recommendations focus on expanding public drug coverage and implementing cost-control measures.
Related Concept Videos
01:18Introduction To Health Care Delivery System
4.6K
The healthcare system is constantly changing and complex. Various services are available from different healthcare providers, but gaining access to these services has become challenging for people with limited healthcare insurance. Uninsured people present a challenge to healthcare because they frequently postpone or forego treatment.
The Institute of Medicine (IOM) advocates for a patient-centered, effective, safe, timely, equitable, and effective healthcare system. The National Priorities...
The Institute of Medicine (IOM) advocates for a patient-centered, effective, safe, timely, equitable, and effective healthcare system. The National Priorities...
4.6K
01:15Drug Dosing: Geriatric Patients
368
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
368
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
224
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
224
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
228
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
228
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
356
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
356
01:24Dosage Regimen: Individualization
373
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
373